Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports

•Teriflunomide is an oral first-line therapy used in relapsing forms of MS.•The washout period of teriflunomide may be accelerated by cholestyramine.•Clearance of teriflunomide (

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2020-06, Vol.41, p.102017, Article 102017
Main Authors: Fuerte-Hortigón, A, López Ruiz, R, Hiraldo, JDG, Sánchez Fernández, F, Dotor García-Soto, J, Páramo, María Dolores, Ruiz-Peña, JL, Navarro-Mascarell, G, Eichau, S
Format: Article
Language:English
Subjects:
Accelerated elimination procedure
Adult
Anion Exchange Resins - administration & dosage
Cholestyramine
Cholestyramine Resin - administration & dosage
Crotonates - blood
Crotonates - pharmacokinetics
Female
Humans
Immunologic Factors - blood
Immunologic Factors - pharmacokinetics
Male
Multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Multiple Sclerosis, Relapsing-Remitting - physiopathology
Recurrence
Teriflunomide
Toluidines - blood
Toluidines - pharmacokinetics
Tumefactive lesion
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Teriflunomide is an oral first-line therapy used in relapsing forms of MS.•The washout period of teriflunomide may be accelerated by cholestyramine.•Clearance of teriflunomide (
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2020.102017